GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04827589
Study of Magrolimab in Patients With Solid Tumors
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04827576
- Locations
- 🇺🇸
Tallahassee Memorial Healthcare Cancer Center, Tallahassee, Florida, United States
🇺🇸University of Miami, Deerfield Beach, Florida, United States
🇺🇸Virginia Piper Cancer Center (Alliant Health), Saint Paul, Minnesota, United States
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT04811040
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care, Greenville, North Carolina, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT04809623
- Locations
- 🇺🇸
Wallace Rheumatic Studies Center, LLC, Beverly Hills, California, United States
🇺🇸DJL Clinical Research, PLLC, Charlotte, North Carolina, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Myeloid Malignancies
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Steroidal Eye Drops
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT04747470
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸NEXT oncology, San Antonio, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 249
- Registration Number
- NCT04745351
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 331
- Registration Number
- NCT04639986
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Conditions
- Advanced or Metastatic Solid TumorLiver Failure
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04617522
- Locations
- 🇺🇸
Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States